63 3 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO 15. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapyinduced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9. 16. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, doubledummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24. 17. Brugnatelli S, Gattoni E, Grasso D et al. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 2011;97:362-6. 18. Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011;19:1217-25. 19. Kaushal J, Gupta MC, Kaushal V et al. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J 2010;51:871-5. 20. Tian W, Wang Z, Zhou J et al. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapyinduced nausea and vomiting in a Chinese population. Med Oncol 2011;28:71-8. 21. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study. Support Care Cancer 2010;18:423-31. 22. Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 2012;20:14718. 23. Tanioka M, Kitao A, Matsumoto K et al. A randomised, placebo-controlled, doubleblind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013;109:859-65. 24. Gralla R, Bosnjak S, Hontsa A et al. A Phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014;25:1333-9 25. Tan L, Liu J, Liu X et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:131. 26. Zang J, Hou M, Gou HF et al. Antiemetic activity of megestrol acetate in patients receiving chemotherapy. Support Care Cancer 2011;19:667-73. 27. Roscoe JA, Heckler CE, Morrow GR et al. Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 2012;30:3389-95.
RkJQdWJsaXNoZXIy MjY0ODMw